Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment–specific patient-reported outcome measure
Authors' conclusion
We describe an international qualitative study to develop candidate items for a treatment-specific PROM for patients with rheumatic diseases.
Study context
- Population
- Patients from the UK, USA and Australia treated for a rheumatic condition with glucocorticoids (GCs) in the last 2 years39/60 female
- Participants
- 60 patients
- Comparison
- UK vs USA vs Australia
- UKn = 34
- USAn = 10
- Australian = 16
- Outcome
- Impact of GC therapy on health-related quality of life (HRQoL), to inform development of a treatment-specific patient-reported outcome measure (PROM)
Methodological detailssemi-structured interviews, purposive sampling, international (UK, USA, Australia), inductive analysis
- Semi-structured interviews
- Purposive sampling
- International (UK, USA, Australia)
- Inductive analysis
Main finding
As reported in the abstract
Individual themes identified
126
Domains: physical symptoms; psychological symptoms; psychological impact of steroids; impact on participation; impact on relationships; benefits of steroids
6
Mean age, years
58
Rheumatic diseases represented
18
Original publication
Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment–specific patient-reported outcome measure. Rheumatology (Oxford). Published 25 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →